Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

Proteome Analysis

Below the proteome analysis is presented. The analysis methods are presented in the paper Propagating Differential Gene Expression in Protein Interaction Networks. If you are interested in the most reliable results choose the

  • value_type as 'ranked' since this provides a very robust analysis method.
  • intercation map as 'high confidence'
  • network_comparison type as 'Divided' since this leads to a natural grouping of similar proteins
  • filtered as 'true' since this will only use the microarray measurements that have a sufficiently large confidence level.

    • Navigation/Query Panel:
    Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
    Rank Gene description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
    Results: HTML CSV LaTeX Showing element 1150 to 1199 of 3228 in total 
    Value Type: Ranked
    Network Comparison Type: Divided
    Interaction Map: High confidence
    Filtered: 1
    
\def\wcA{0.16666666666667\textwidth}
\def\wcB{0.16666666666667\textwidth}
\def\wcC{0.16666666666667\textwidth}
\def\wcD{0.16666666666667\textwidth}
\def\wcE{0.16666666666667\textwidth}
\begin{longtable}{|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1150\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
sorting nexin 1. [source:swissprot;acc:q13596]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
209.868\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
215.522\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02694\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1151\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
metaxin 1. [source:swissprot;acc:q13505]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
199.552\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
204.925\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02693\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1152\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
epidermal growth factor receptor pathway substrate 8-like protein 1 isoform c; epidermal growth factor receptor pathway substrate 8-related protein 1; eps8-related protein 1. [source:refseq;acc:nm\_139204]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
221.939\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
216.143\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02682\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1153\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
epidermal growth factor receptor kinase substrate eps8. [source:swissprot;acc:q12929]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
221.93\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
216.146\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02676\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1154\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
inorganic pyrophosphatase (ec 3.6.1.1) (pyrophosphate phospho- hydrolase) (ppase). [source:swissprot;acc:q15181]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
224.307\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
230.242\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.02646\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1155\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
inorganic pyrophosphatase 2 isoform 1. [source:refseq;acc:nm\_176869]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1156\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
aryl-hydrocarbon interacting protein-like 1. [source:swissprot;acc:q9nzn9]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1157\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ah receptor-interacting protein (aip) (immunophilin homolog ara9) (hbv-x associated protein 2). [source:swissprot;acc:o00170]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1158\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
epidermal growth factor receptor pathway substrate 8-like protein 2; eps8-related protein 2; epidermal growth factor receptor pathway substrate 8-related protein 2. [source:refseq;acc:nm\_022772]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
221.877\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
216.167\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.02641\vspace{3pt}}}\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
1159\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
proline synthetase co-transcribed bacterial homolog protein. [source:swissprot;acc:o94903]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
170.28\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
165.898\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1160\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2-oxoglutarate dehydrogenase e1 component, mitochondrial precursor (ec 1.2.4.2) (alpha-ketoglutarate dehydrogenase). [source:swissprot;acc:q02218]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
208.55\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
214.041\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02633\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1161\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
kappa b-ras 1. [source:refseq;acc:nm\_020345]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
220.758\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
215.097\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.02632\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1162\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
i-kappa-b-interacting ras-like protein 2. [source:refseq;acc:nm\_017595]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1163\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
snare associated protein snapin. [source:refseq;acc:nm\_012437]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1164\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
transducin-like enhancer protein 4. [source:swissprot;acc:q04727]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
219.438\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.818\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02628\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1165\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
transducin-like enhancer protein 3 (esg3). [source:swissprot;acc:q04726]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
219.401\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.785\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.02627\vspace{3pt}}}\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
1166\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
transducin-like enhancer protein 2 (esg2). [source:swissprot;acc:q04725]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
219.374\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.759\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1167\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
homeobox protein engrailed-2 (hu-en-2). [source:swissprot;acc:p19622]\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
219.399\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
213.784\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.02626\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1168\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
cpg binding protein (protein containing phd finger and cxxc domain 1). [source:swissprot;acc:q9p0u4]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1169\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
activator of basal transcription 1; tata-binding protein-binding protein; basal transcriptional activator. [source:refseq;acc:nm\_013375]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1170\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
cytokine-like nuclear factor n-pac. [source:refseq;acc:nm\_032569]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1171\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
hect type e3 ubiquitin ligase. [source:refseq;acc:nm\_015052]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1172\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
transducin-like enhancer protein 1 (esg1). [source:swissprot;acc:q04724]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
219.375\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.767\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02623\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1173\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
candidate tumor suppressor in ovarian cancer 2. [source:refseq;acc:nm\_080822]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
229.243\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
235.246\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02619\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1174\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
coatomer epsilon subunit (epsilon-coat protein) (epsilon-cop). [source:swissprot;acc:o14579]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
187.964\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
192.849\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02599\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1175\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
vacuolar atp synthase 16 kda proteolipid subunit (ec 3.6.3.14). [source:swissprot;acc:p27449]\vspace{3pt}}&\multirow{7}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
218.186\vspace{3pt}}}&\multirow{7}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
212.672\vspace{3pt}}}&\multirow{7}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.02593\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1176\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
sarcoglycan zeta; zeta-sarcoglycan. [source:refseq;acc:nm\_139167]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1177\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
golgi complex associated protein 1; golgi resident protein gcp60; peripherial benzodiazepine receptor associated protein; golgi phosphoprotein 1; pbr associated protein; pka (rialpha)-associated protein. [source:refseq;acc:nm\_022735]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1178\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
delta-sarcoglycan (sg-delta) (35 kda dystrophin-associated glycoprotein) (35dag). [source:swissprot;acc:q92629]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1179\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
cellular modulator of immune recognition. [source:refseq;acc:nm\_145021]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1180\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
vacuolar atp synthase 21 kda proteolipid subunit (ec 3.6.3.14) (hatpl). [source:swissprot;acc:q99437]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1181\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
gamma-sarcoglycan (gamma-sg) (35 kda dystrophin-associated glycoprotein) (35dag). [source:swissprot;acc:q13326]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1182\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
neurocalcin delta. [source:swissprot;acc:p29554]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
225.104\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
230.931\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02589\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1183\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
neuron specific calcium-binding protein hippocalcin (p23k) (calcium- binding protein bdr-2). [source:swissprot;acc:p32076]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
225.103\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
230.928\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02588\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1184\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
arf gtpase-activating protein git1 (g protein-coupled receptor kinase- interactor 1). [source:swissprot;acc:q9y2x7]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
216.729\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
222.334\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02586\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1185\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
visinin-like protein 3 (vilip-3) (calcium-binding protein bdr-1) (hlp2) (hippocalcin-like protein 1). [source:swissprot;acc:p37235]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
225.094\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
230.913\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02585\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1186\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
adp-ribosylation factor-like protein 7 (adp-ribosylation factor-like protein lak). [source:swissprot;acc:p56559]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
218.402\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
212.904\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.02582\vspace{3pt}}}\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1187\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
vacuolar atp synthase subunit d (ec 3.6.3.14) (v-atpase d subunit) (vacuolar proton pump d subunit) (v-atpase ac39 subunit) (v-atpase 40 kda accessory protein) (p39) (32 kda accessory protein). [source:swissprot;acc:p12953]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1188\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
adp-ribosylation factor-like protein 4. [source:swissprot;acc:p40617]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1189\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
alpha-1-acid glycoprotein 2 precursor (agp 2) (orosomucoid 2) (omd 2). [source:swissprot;acc:p19652]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
209.649\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
204.406\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02565\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1190\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ubiquitin. [source:swissprot;acc:p02248]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
209.6\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
204.372\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
1.02558\vspace{3pt}}}\\\cline{1-4}
\parbox{\wcA}{\vspace{3pt}\noindent
1191\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
upstream binding protein 1 (lbp-1a). [source:refseq;acc:nm\_014517]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
220.742\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
215.237\vspace{3pt}}}&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1192\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
transcription factor cp2; transcription factor cp2, alpha globin. [source:refseq;acc:nm\_005653]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1193\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
lbp-9. [source:refseq;acc:nm\_014553]\vspace{3pt}}&&&\\\cline{1-2}
\parbox{\wcA}{\vspace{3pt}\noindent
1194\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
splicing factor, arginine/serine-rich 3 (pre-mrna splicing factor srp20) (x16 protein). [source:swissprot;acc:p23152]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1195\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
skeletal muscle lim-protein 3 (slim 3) (lim-domain protein dral) (four and a half lim domains protein 2) (fhl-2). [source:swissprot;acc:q14192]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
269.608\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
276.493\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02554\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1196\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
kinesin protein. [source:refseq;acc:nm\_032559]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
224.858\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
219.264\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02551\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1197\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
mstp028 protein. [source:refseq;acc:nm\_031954]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
219.042\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.6\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02548\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1198\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
skeletal muscle lim-protein 2 (slim 2) (four and a half lim domains protein 3) (fhl-3). [source:swissprot;acc:q13643]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
269.59\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
276.454\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02546\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1199\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
u3 small nucleolar ribonucleoprotein protein mpp10 (m phase phosphoprotein 10). [source:swissprot;acc:o00566]\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
241.496\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
235.508\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.02543\vspace{3pt}}\\\hline
nd{longtable}

    Legend:
    - Rank is the rank after comparing the two networks
    
 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray
    
 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.
    
 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them
    
 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.
    
 - Filtered specifies whether we only included the high confidence microarry measurements or not.
    - http://analysis.yellowcouch.org/